SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 195.19 |
| Enterprise Value ($M) | 187.97 |
| Book Value ($M) | 60.49 |
| Book Value / Share | 0.68 |
| Price / Book | 3.23 |
| NCAV ($M) | 51.80 |
| NCAV / Share | 0.58 |
| Price / NCAV | 3.77 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.03 |
| Return on Assets (ROA) | 0.01 |
| Return on Equity (ROE) | 0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.14 |
| Current Ratio | 4.14 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 114.83 |
| Assets | 123.52 |
| Liabilities | 63.03 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Bristol Myers Squibb Co |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 69,486 | 294,569 | 23.59 | |
| 98,201 | 323,862 | 30.32 | |
| 38,427 | 361,722 | 10.62 | |
| 70,204 | 494,178 | 14.21 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CDXC – ChromaDex Corporation | CELU – Celularity Inc. |
| CELZ – Creative Medical Technology Holdings, Inc. | CING – Cingulate Inc. |
| CKPT – Checkpoint Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io